Plain-English translation of NCT07135544 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Biliary Tract Cancer research guide →Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This study is testing a new treatment approach for bile duct cancer that has spread or cannot be surgically removed. The treatment combines three medications: Adebrelimab (an immune-boosting antibody), Apatinib (a targeted therapy), and two chemotherapy drugs called gemcitabine and cisplatin. Researchers want to see if using all three together works better than current standard treatments.
Bile duct cancer is an aggressive disease, and many patients are diagnosed when surgery is no longer an option. Current treatments have limited success, so this trial explores whether adding an immune-boosting medication to the standard chemotherapy and targeted therapy combination might help more patients and extend their survival.
You likely qualify if…
You likely don't qualify if…
You would visit the research center regularly over several months to receive the three-drug treatment. Adebrelimab is given through an IV infusion once every three weeks, while chemotherapy drugs are given through IV on specific days within each three-week cycle. You would take Apatinib as an oral pill daily at home. Throughout the trial, you'll have blood tests and imaging scans to monitor how well the treatment is working and to watch for any side effects. The study will track about 37 patients total to see if this combination helps people with this type of cancer.
AI-generated summary from trial data · Oct 12, 2026 · Not medical advice
China